Two patterns of changes in nasal nitric oxide after lysine aspirin nasal challenge in patients with aspirin-exacerbated respiratory disease

American Journal of Rhinology and Allergy

Volumn 26, Issue 6, 2012, Pages 428-432

  Tworek, Damian ^a   Kuprys Lipinska, Izabela ^b   Pietruszewska, Wioletta ^b   Kuna, Piotr ^b  

^a Barlicki University Hospital ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ASPIRIN IV; LYSINE ACETYLSALICYLATE; NITRIC OXIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MALE; MEASUREMENT; NOSE POLYP; OUTCOME ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE;

ADMINISTRATION, INTRANASAL; ADULT; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; FEMALE; HUMANS; LYSINE; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL PROVOCATION TESTS; NITRIC OXIDE; PAIN MEASUREMENT; SINGLE-BLIND METHOD;

EID: 84871047455     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2012.26.3818     Document Type: Article

References (25)

1. Palmer RM, Ferrige AG, and Moncada S. Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor. Nature 327:524-326, 1987.
2. Gustafsson LE, Leone AM, Persson MG, et al. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 181:852-857, 1991.
3. Alving K, Weitzberg E, and Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 6:1368-1370, 1993. (Pubitemid 23329557)
4. Lundberg JO, Farkas-Szallasi T, Weitzberg E, et al. High nitric oxide production in human paranasal sinuses. Nat Med 1:370-373, 1995.
5. Djupesland PG, Chatkin JM, Qian W, and Haight JS. Nitric oxide in the nasal airway: A new dimension in otorhinolaryngology. Am J Otolaryngol 22:19-32, 2001. (Pubitemid 32156412)
6. Kim JW, Min YG, Rhee CS, et al. Regulation of mucociliary motility by nitric oxide and expression of nitric oxide synthase in the human sinus epithelial cells. Laryngoscope 111:246-250, 2001.
7. Chang JE, White A, Simon RA, and Stevenson DD. Aspirin-exacerbated respiratory disease: Burden of disease. Allergy Asthma Proc 33:117-121, 2012.
8. Chang JE, Chin W, and Simon R. Aspirin-sensitive asthma and upper airway diseases. Am J Rhinol Allergy 26:27-30, 2012.
9. Pedrosa M, Barranco P, López-Carrasco V, et al. Changes in exhaled nitric oxide levels after bronchial allergen challenge. Lung 190:209-214, 2012.
10. Rolla G, Di Emanuele A, Dutto L, et al. Effect of inhalation aspirin challenge on exhaled nitric oxide in patients with aspirin-inducible asthma. Allergy 59:827-832, 2004. (Pubitemid 39005822)
11. Boot JD, de Kam ML, Mascelli MA, et al. Nasal nitric oxide: Longitudinal reproducibility and the effects of a nasal allergen challenge in patients with allergic rhinitis. Allergy 62:378-384, 2007. (Pubitemid 46398806)
12. Tworek D, and Kuna P. Nasal nitric oxide measurements in the assessment of nasal allergen challenge. J Investig Allergol Clin Immunol 22:102-108, 2012.
13. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/GA2LEN guideline: Aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 62:1111-1118, 2007. (Pubitemid 47374015)
14. Milewski M, Mastalerz L, Nizankowska E, and Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 101:581-586, 1998.
15. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 26:319-338, 2005. (Pubitemid 41079078)
16. Parikh A, Scadding GK, Gray P, et al. High levels of nitric oxide synthase activity are associated with nasal polyp tissue from aspirin-sensitive asthmatics. Acta Otolaryngol 122:302-305, 2002. (Pubitemid 34538931)
17. Zhang Y, Endam LM, Filali-Mouhim A, et al. Polymorphisms in the nitric oxide synthase 1 gene are associated with severe chronic rhinosinusitis. Am J Rhinol Allergy 25:e49-e54, 2011.
18. Bommarito L, Guida G, Heffler E, et al. Nasal nitric oxide concentration in suspected chronic rhinosinusitis. Ann Allergy Asthma Immunol 101:358-362, 2008.
19. Ragab SM, Lund VJ, Saleh HA, and Scadding G. Nasal nitric oxide in objective evaluation of chronic rhinosinusitis therapy. Allergy 61:717-724, 2006. (Pubitemid 43801406)
20. Ogata N, Darby Y, and Scadding G. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol 121:1156-1160, 2007. (Pubitemid 351650718)
21. Fuentes-Beltrán A, Montes-Vizuet R, Valencia-Maqueda E, et al. Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients. Clin Exp Allergy 39:491-499, 2009.
22. Kowalski ML, Grzegorczyk J, Wojciechowska B, and Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 26:807-814, 1996. (Pubitemid 26266427)
23. Kupczyk M, Antczak A, Kuprys-Lipinska I, and Kuna P. Lipoxin A4 generation is decreased in aspirin-sensitive patients in lysine-aspirin nasal challenge in vivo model. Allergy 64:1746-1752, 2009.
24. Casadevall J, Ventura PJ, Mullol J, and Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: Evaluation of nasal response by acoustic rhinometry. Thorax 55:921-924, 2000.
25. González-Pérez R, Poza-Guedes P, and Vives-Conesa R. The nose as a target organ in the diagnosis of severe aspirin-exacerbated respiratory disease. Am J Rhinol Allergy 25:166-169, 2011.